Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-Scz-1: Brenipatide as Adjunctive Treatment in Adults with Schizophrenia
jRCT2021250053Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Modality
- Peptides
01
Overview
Phase 2, randomised, double-blind trial in schizophrenia comparing Brenipatide + standard-of-care with Placebo + standard-of-care (2 arms). Primary endpoint: Percent change from baseline in body weight. Started Feb 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2021250053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250053.